Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Bolt Biotherapeutics (BOLT) over the last 7 years, with Q3 2025 value amounting to $65.1 million.

  • Bolt Biotherapeutics' Liabilities and Shareholders Equity fell 4050.07% to $65.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $326.0 million, marking a year-over-year decrease of 3919.16%. This contributed to the annual value of $99.6 million for FY2024, which is 3764.58% down from last year.
  • Per Bolt Biotherapeutics' latest filing, its Liabilities and Shareholders Equity stood at $65.1 million for Q3 2025, which was down 4050.07% from $75.5 million recorded in Q2 2025.
  • Over the past 5 years, Bolt Biotherapeutics' Liabilities and Shareholders Equity peaked at $347.1 million during Q2 2021, and registered a low of $65.1 million during Q3 2025.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $190.7 million (2023), whereas its average is $198.1 million.
  • As far as peak fluctuations go, Bolt Biotherapeutics' Liabilities and Shareholders Equity soared by 56116.2% in 2021, and later tumbled by 4050.07% in 2025.
  • Quarter analysis of 5 years shows Bolt Biotherapeutics' Liabilities and Shareholders Equity stood at $307.7 million in 2021, then fell by 25.97% to $227.8 million in 2022, then fell by 29.86% to $159.8 million in 2023, then tumbled by 37.65% to $99.6 million in 2024, then tumbled by 34.71% to $65.1 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $65.1 million for Q3 2025, versus $75.5 million for Q2 2025 and $85.9 million for Q1 2025.